Search
NuCana PLC
NCNAAdd to Watchlist
1.590USD
+0.110+7.43%
Close 08-14 16:00（ET）Quotes delayed by 15 min
6.85MMarket Cap
0.03P/E TTM
More Details of NuCana PLC Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC Profile
Ticker SymbolNCNA
Company nameNuCana PLC
IPO dateSep 28, 2017
CEO- -
Number of employees20
Security typeDepository Receipt
Fiscal year-endSep 28
AddressLochside House
CityEDINBURGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeEH12 9DT
Phone4401313571111
Websitehttps://www.nucana.com/
Ticker SymbolNCNA
IPO dateSep 28, 2017
CEO- -
Company Executives of NuCana PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
FAQs
Who are the top five shareholders of NuCana PLC?
The top five shareholders of NuCana PLC are: Mr. Hugh S. Griffith
How many institutions hold shares of NuCana PLC (NCNA)?
As of 2026Q1, 46 institutions hold shares of NuCana PLC, with a combined market value of approximately 32.77K, accounting for 0.79% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -151989.00.